Crinetics Pharmaceuticals (CRNX) News Today $30.16 -0.34 (-1.11%) Closing price 04:00 PM EasternExtended Trading$30.50 +0.34 (+1.13%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CRNX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Stephen F. Betz Sells 97,483 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) StockJune 17 at 4:32 AM | insidertrades.comInsider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells 97,483 Shares of StockCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Stephen F. Betz sold 97,483 shares of the company's stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $32.23, for a total value of $3,141,877.09. Following the completion of the transaction, the insider now directly owns 99,713 shares of the company's stock, valued at approximately $3,213,749.99. This trade represents a 49.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.June 16, 2025 | marketbeat.comCrinetics Pharmaceuticals to Host R&D Day on June 26, 2025June 16, 2025 | globenewswire.comCrinetics Pharmaceuticals: Highly Priced Biotech Awaits PDUFA On Acromegaly DrugJune 16, 2025 | seekingalpha.comRhumbline Advisers Increases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Rhumbline Advisers boosted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 6.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 131,950 shares of the company's stock after purchasing an additiJune 14, 2025 | marketbeat.comBrokers Offer Predictions for CRNX FY2026 EarningsJune 12, 2025 | americanbankingnews.comSG Americas Securities LLC Decreases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)SG Americas Securities LLC reduced its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 3.7% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 522,266 shares of the company's stock after selling 20,180 shJune 11, 2025 | marketbeat.comCrinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 10, 2025 | globenewswire.comAnalysts Offer Predictions for CRNX FY2026 EarningsCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Crinetics Pharmaceuticals in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post eJune 10, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 14,300 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Two Sigma Advisers LP reduced its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 63.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,100 shares of the company's stock after sellJune 5, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by California State Teachers Retirement SystemCalifornia State Teachers Retirement System increased its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 18.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 76,264 shares of the company'sJune 4, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and ten have issued a buy ratingJune 2, 2025 | marketbeat.comJane Street Group LLC Sells 122,188 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Jane Street Group LLC cut its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 94.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 7,404 shares of the company's stock after selling 122,188 shares duringJune 1, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Invests $17.12 Million in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 334,783 shares of the company's stock, valued at apMay 31, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 53,529 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 19.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The iMay 30, 2025 | marketbeat.comWoodline Partners LP Makes New $2.56 Million Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Woodline Partners LP acquired a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 50,000 shares of the company's stMay 27, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Position Lessened by D. E. Shaw & Co. Inc.D. E. Shaw & Co. Inc. reduced its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 85.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,876 shares of the company's stock after sMay 27, 2025 | marketbeat.comNuveen Asset Management LLC Boosts Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Nuveen Asset Management LLC raised its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 2.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 527,792 shares of the company's stock afMay 25, 2025 | marketbeat.comBank of America Corp DE Decreases Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Bank of America Corp DE decreased its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 15.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 235,281 shares of the company's stock after selling 4May 25, 2025 | marketbeat.comProShare Advisors LLC Acquires 9,655 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)ProShare Advisors LLC grew its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 49.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 29,089 shares of the company's stock after purchasing an additional 9,655 shares duringMay 24, 2025 | marketbeat.comCrinetics Pharmaceuticals’ SWOT analysis: oral endocrine drug stock poised for growthMay 23, 2025 | investing.comCrinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025May 23, 2025 | globenewswire.com85,000 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Purchased by Soleus Capital Management L.P.Soleus Capital Management L.P. bought a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 85,000 shares of the company's sMay 21, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Rafferty Asset Management LLCRafferty Asset Management LLC lowered its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 16.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 81,257 shares of the company's stock afterMay 21, 2025 | marketbeat.comTema Etfs LLC Takes Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Tema Etfs LLC purchased a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 57,933 shares of the company's stock, valued at approximately $2,962,000. Crinetics Pharmaceuticals accoMay 20, 2025 | marketbeat.comAmeriprise Financial Inc. Purchases 186,681 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Ameriprise Financial Inc. raised its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 110.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 355,174 shares of the company's stock aMay 18, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Point72 Asset Management L.P.Point72 Asset Management L.P. lifted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 21.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,788,939 shares of the company's stock after buying an aMay 17, 2025 | marketbeat.comMPM Bioimpact LLC Purchases 91,190 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)MPM Bioimpact LLC lifted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 17.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 617,035 shares of the company's stock after purchasing an aMay 16, 2025 | marketbeat.comParkman Healthcare Partners LLC Reduces Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Parkman Healthcare Partners LLC lowered its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 34.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,133 shares of the comMay 16, 2025 | marketbeat.comParadigm Biocapital Advisors LP Sells 605,925 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Paradigm Biocapital Advisors LP reduced its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 24.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 1,910,761 shares of the company's stock after selling 605,925 shares duMay 16, 2025 | marketbeat.comCantor Fitzgerald Weighs in on CRNX FY2025 EarningsCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Research analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of Crinetics Pharmaceuticals in a report issued on Monday, May 12th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post eaMay 16, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Holdings Lifted by Nicholas Investment Partners LPNicholas Investment Partners LP boosted its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 35.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 127,283 shares of the company's stock afMay 16, 2025 | marketbeat.comCrinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025May 15, 2025 | globenewswire.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Orbimed Advisors LLCOrbimed Advisors LLC trimmed its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 4.9% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 999,000 shares of the company's stock after selling 51,055 shares during thMay 15, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Janus Henderson Group PLCJanus Henderson Group PLC lifted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 15.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,795,441 shares of the company's stock after purchasingMay 15, 2025 | marketbeat.comEnsign Peak Advisors Inc Sells 114,147 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Ensign Peak Advisors Inc reduced its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 18.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 502,690 shares of the company's stock aftMay 13, 2025 | marketbeat.comCrinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2025 | finance.yahoo.comCrinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2025 | globenewswire.comBrevan Howard Capital Management LP Takes $500,000 Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Brevan Howard Capital Management LP bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 9,777 shares of the company's stock, valued at approximately $500,000. Several otMay 12, 2025 | marketbeat.comAlgert Global LLC Lowers Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Algert Global LLC cut its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 32.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 28,777 shares of the company's stock aftMay 12, 2025 | marketbeat.comFarallon Capital Management LLC Boosts Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Farallon Capital Management LLC raised its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 250.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,075,098 shares oMay 11, 2025 | marketbeat.comNorthern Trust Corp Has $44.99 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Northern Trust Corp lifted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 20.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 879,814 shares of the company's stock after purchasing an additionalMay 11, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comCrinetics Pharmaceuticals, Inc (CRNX) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stake Increased by Driehaus Capital Management LLCDriehaus Capital Management LLC grew its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 4.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,141,014 shares of the company's stock after purchasing anMay 10, 2025 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on April 17th. The tradMay 10, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have earned an average rating of "Moderate Buy" from the thirteen ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and twelve have issued a buy reMay 10, 2025 | marketbeat.comIs Crinetics Pharmaceuticals, Inc. (CRNX) The Best Stock That Will Bounce Back?May 9, 2025 | msn.comDuquesne Family Office LLC Cuts Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Duquesne Family Office LLC trimmed its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 60.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 122,700 shares of the company'sMay 9, 2025 | marketbeat.comCrinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 9, 2025 | finance.yahoo.com Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address CRNX Media Mentions By Week CRNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRNX News Sentiment▼0.630.68▲Average Medical News Sentiment CRNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRNX Articles This Week▼67▲CRNX Articles Average Week Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ascendis Pharma A/S News Today Viatris News Today Qiagen News Today Moderna News Today Blueprint Medicines News Today BridgeBio Pharma News Today Roivant Sciences News Today Verona Pharma News Today Revolution Medicines News Today Elanco Animal Health News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRNX) was last updated on 6/20/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Biggest Story of My Decade-Long Career in Silicon ValleySteve Jobs' Lost 'Product' Could Save Tesla On July 21st, a revolutionary announcement could transform Tesl...InvestorPlace | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis is your first (and maybe last) chanceGet in before Monday if you want true wealth. In the 46 year storied existence of Zacks Investment Research… ...Zacks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRNX Stock Free CRNX Stock Alerts